Patents Pending

Patents Pending

Eleven filed U.S. provisional patent applications protecting BioLabs™ core innovations within the BioCube™ Platform.

IP Strategy

Multi-Layer IP Protection

BioLabs™' IP is not just a crop — it's a system. We build IP strategies through multiple layers of protection, from filed process patents to proprietary trade secrets, clinical frameworks and certification advantages.

Process Patents
Filed patent applications protecting novel growing system architectures and methods
Trade Secrets
Proprietary spectra, fertigation schedules and nutrient pathways retained as confidential IP
Digital Growth Algorithms
Proprietary optimisation systems for closed-loop environmental control
Clinical Nutrient-Profile Mapping
Unique bioactive frameworks linking grow parameters to clinical outcomes
Certification Advantage
GACP, ISO 22000, HACCP compliance as a defensible moat
11
Patent Applications Filed
All invented by Dr P. Hilton
40+
Total Patents (Group)
Including advisory board holding 40+ CEA patents
80–90%
Licensing Margins
IP and protocol licensing revenue projection
Intellectual Property

Filed Patent Applications

BioLabs’ intellectual-property portfolio now comprises eleven filed U.S. provisional patent applications covering controlled-environment agriculture, biological production systems, bioencapsulation, sensing, automation and related platform technologies. Select an application below to view a technical summary and representative patent drawing.

Patent Ref: 64/005,593
Inventor: Dr P. Hilton

Aeroponic Root-Zone Apparatus and Pulsed Misting Control for Woody Perennial and Rhizome Crops in Controlled-Environment Modules

FIG. A — Aeroponic Root-Zone Cross-Section
Patent Ref: 64/005,623
Inventor: Dr P. Hilton

Assay-Linked Closed-Loop Controlled-Environment Cultivation to Produce Standardised Bioactive Profiles in Nutraceutical Ingredients

FIG. B3 — Target Window vs Measured Value with Control Response
Patent Ref: 64/005,630
Inventor: Dr P. Hilton

Rapid Reconfiguration Multi-Crop Cassette System with Quick-Connect Utilities and Validated Sanitation Workflow for Controlled-Environment Modules

FIG. C5 — Cassette Sanitation & Batch Validation Flow
Patent Ref: 63/993,711
Inventor: Dr P. Hilton

High-Density Multi-Tier Camellia Sinensis Cultivation System Using Plucking-Table Canopy Training and Modular Root-Zone Fixtures

FIG. 1–4 — Multi-Tier Camellia Sinensis Cultivation System
Patent Ref: 63/992,073
Inventor: Dr P. Hilton

Programmable Shade-Cycle and Spectral Control System for Producing Matcha-Grade Camellia Sinensis in a Controlled-Environment Module

FIG. 1–5 — Shade-Cycle & Spectral Control Architecture
Bioencapsulated Peptide Systems

BPS Patent Family

Filed on 12 October 2026, the BPS patent family comprises six coordinated U.S. provisional patent applications directed to complementary elements of the BioLabs Bioencapsulated Peptide Systems platform.

Patent PendingU.S. Provisional Application No. 64/174,222
Inventor: Dr P. Hilton

Bioencapsulated Peptide Systems Platform and Methods Therefor

FIG. U1 — Integrated Bioencapsulated Peptide Systems architecture showing cultivation, monitoring, processing, analytical verification, formulation and supervisory control.
Patent PendingU.S. Provisional Application No. 64/174,226
Inventor: Dr P. Hilton

Edible Biological Chassis and Oral Bioencapsulation Platform

FIG. B1-3 — Representative gastrointestinal protection and controlled-release pathway for a bioencapsulated therapeutic payload.
Patent PendingU.S. Provisional Application No. 64/174,230
Inventor: Dr P. Hilton

Controlled-Environment Production, Standardisation and Dose Normalisation of Bioencapsulated Therapeutic Biomass

FIG. B2-1 — Controlled-environment therapeutic production cell incorporating cultivation infrastructure, environmental control, monitoring and batch-management systems.
Patent PendingU.S. Provisional Application No. 64/174,231
Inventor: Dr P. Hilton

Sensor-Guided Biological Readiness Detection and Closed-Loop Actuation for Bioencapsulated Therapeutic Production

FIG. B3-2 — Representative stomatal and tissue-readiness imaging architecture for biological-state assessment prior to controlled actuation.
Patent PendingU.S. Provisional Application No. 64/174,232
Inventor: Dr P. Hilton

Automated Harvest, Formulation and Inline Quality Release of Bioencapsulated Peptide Doses

FIG. 4A — Automated harvest, formulation and inline quality-control cell showing material transfer, analytical verification and release/reject routing.
Patent PendingU.S. Provisional Application No. 64/174,233
Inventor: Dr P. Hilton

Autonomous Closed-Loop Bioencapsulated Therapeutic Production Platform

FIG. B5-6 — Resource-integrated autonomous BPS production cell showing energy and environmental inputs, therapeutic outputs and waste/recycle interfaces.

Partners & Associates

UK Urban Agritech
East Suffolk Council
Growspec Global
NutraGenesis
OREX
Synergy Sphere
UK Urban Agritech
East Suffolk Council
Growspec Global
NutraGenesis
OREX
Synergy Sphere
BioLabs

The Operating System for Biologicals

EIS Round 3 Open

Navigation

Registered Office

Oxford Science Park
Oxford, OX4 4GA, UK
Co. Reg.: 15812659

Sales & Distribution

Unit 16,
Nexus Power Park
Lowestoft, NR32 1XA

In Silico Lab

Stirling University
Innovation Park
Stirling, FK9 4NF
"BioLabs™" is a Trading Style of Frontier Biolabs Ltd and Biolabs Corp Ltd

Regulatory Status

Biolabs Corp Ltd is authorised and regulated by the Financial Conduct Authority (Firm Reference Number: 1051225).

Regulatory Disclaimer

Biolabs Corp Ltd is listed on the FCA Financial Services Register under FRN 1051225. Check our registration details on register.fca.org.uk . Investment in early-stage ventures involves significant risk, including illiquidity, lack of dividends, loss of capital, and dilution.

© 2026 BioLabs. All rights reserved.